Stockscreener 앱 받기
32.74
2.15%
0.69
시간 외 거래:
31.49
-1.25
-3.82%
전일 마감가:
$32.05
열려 있는:
$31.76
하루 거래량:
469.78K
Relative Volume:
0.96
시가총액:
$2.27B
수익:
-
순이익/손실:
$-179.27M
주가수익비율:
-12.79
EPS:
-2.56
순현금흐름:
$-155.88M
1주 성능:
+3.18%
1개월 성능:
+15.93%
6개월 성능:
+66.53%
1년 성능:
+124.55%
1일 변동 폭
$31.12
$32.75
1주일 범위
$30.12
$32.95
52주 변동 폭
$13.39
$37.00
Akero Therapeutics Inc Stock (AKRO) Company Profile
명칭
Akero Therapeutics Inc
전화
650-487-6488
주소
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-22 | 재개 | BofA Securities | Neutral |
| 2023-09-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-28 | 개시 | UBS | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 개시 | Guggenheim | Buy |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-07-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2020-07-01 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-02 | 개시 | H.C. Wainwright | Buy |
| 2020-02-10 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Evercore ISI | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
| 2019-07-15 | 개시 | Jefferies | Buy |
| 2019-07-15 | 개시 | ROTH Capital | Buy |
모두보기
Akero Therapeutics Inc 주식(AKRO)의 최신 뉴스
Akero Therapeutics COO sells $1.6 million in stock By Investing.com - Investing.com South Africa
Akero Therapeutics COO sells $1.6 million in stock - Investing.com India
Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $1,601,104.12 in Stock - MarketBeat
Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock By Investing.com - Investing.com South Africa
Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock - Investing.com India
abrdn plc Sells 75,879 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 4,515 Shares of Stock - MarketBeat
Akero Therapeutics chief development officer sells $651,960 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics chief development officer sells $651,960 in stock - Investing.com
Akero Therapeutics (NASDAQ:AKRO) Trading Up 5.8%Here's What Happened - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Decline in Short Interest - MarketBeat
Akero Therapeutics to Present Data Reinforcing the Efficacy - GlobeNewswire
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 - StockTitan
Akero Therapeutics Insiders Sell US$1.2m Of Stock, Possibly Signalling Caution - Simply Wall St
(AKRO) Proactive Strategies - Stock Traders Daily
Andrew Cheng Sells 24,992 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Akero Therapeutics CEO Andrew Cheng sells $2.88 million in stock By Investing.com - Investing.com Canada
Akero Therapeutics chief development officer sells $636,490 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics chief development officer sells $636,490 in stock - Investing.com India
State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares - GuruFocus.com
Akero therapeutics COO Jonathan Young sells $1.2 million in stock By Investing.com - Investing.com Australia
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Rheos Capital Works Inc. - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Decrease in Short Interest - MarketBeat
Akero therapeutics COO Jonathan Young sells $1.2 million in stock - Investing.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 6,136 Shares - MarketBeat
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin - Insider Monkey
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds - Insider Monkey
Should investors be concerned about Akero Therapeutics Inc (AKRO)? - US Post News
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
10 Most Promising Small-Cap Stocks According to Hedge Funds - Insider Monkey
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
The Manufacturers Life Insurance Company Purchases 22,195 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Inc [AKRO] Investment Appeal on the Rise - Knox Daily
AKRO’s 2023 Market Dance: Up 20.56% – Time to Invest? - The InvestChronicle
Akero Therapeutics (NASDAQ:AKRO) Shares Up 4.2%Here's Why - MarketBeat
A better buy-in window may exist right now for Akero Therapeutics Inc (AKRO) - SETE News
A company insider recently sold 10,000 shares of Akero Therapeutics Inc [AKRO]. Should You Sale? - Knox Daily
Algert Global LLC Decreases Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics COO sells $281,770 in company stock - Investing.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $281,800.00 in Stock - MarketBeat
Is Akero Therapeutics Inc (AKRO) a good investment opportunity? - US Post News
The Potential Rise in the Price of Akero Therapeutics Inc (AKRO) following insiders activity - Knox Daily
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Longview News-Journal
Top investors say Akero Therapeutics Inc (AKRO) ticks everything they need - SETE News
Perceptive Advisors LLC Purchases 112,426 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference - StockTitan
Akero Therapeutics Inc (AKRO) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
(AKRO) Investment Analysis and Advice - Stock Traders Daily
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus.com
A company insider recently sold 5,500 shares of Akero Therapeutics Inc [AKRO]. Should You Sale? - Knox Daily
Akero Therapeutics Inc (AKRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):